Baseline characteristics of the study patients
| Characteristic . | All patients (N = 532) . | Patients with dnCMML (n = 461) . | Patients with tCMML (n = 71) . | P value . |
|---|---|---|---|---|
| Median age, y (range) | 70 (25-94) | 70 (25-94) | 73 (30-89) | .055 |
| Male sex, n (%) | 358 (67) | 309 (67) | 49 (69) | .844 |
| Median hemoglobin level, g/dL (range) | 10.8 (5.3-17.3) | 10.8 (5.3-17.3) | 10.9 (6.4-15.6) | .530 |
| Median WBC count, ×109 cells/L (range) | 12.6 (2.4-214.0) | 13.3 (2.6-214.0) | 10.7 (2.4-132.9) | .030 |
| Median absolute neutrophil count, ×109 cells/L (range) | 6.5 (0-108.0) | 6.8 (0-108.0) | 5.3 (0.5-50.6) | .100 |
| Median absolute monocyte count, ×109 cells/L (range) | 2.4 (1-74.7) | 2.4 (1-74.7) | 1.9 (1-73.1) | .698 |
| Median platelet count, ×109 cells/L (range) | 101 (7-1386) | 101 (7-1386) | 115 (16-638) | .629 |
| Median bone marrow blast percentage (range) | 6 (0-18) | 6 (0-18) | 5 (1-18) | .879 |
| WHO 2016 classification, n (%) | ||||
| CMML-0 | 206 (39) | 176 (38) | 30 (42) | .840 |
| CMML-1 | 205 (39) | 179 (39) | 26 (37) | |
| CMML-2 | 116 (22) | 101 (22) | 15 (21) | |
| Not classifiable∗ | 5 (1) | 5 (1) | 0 | |
| FAB CMML classification, n (%) | ||||
| Dysplastic | 228 (43) | 193 (42) | 35 (49) | .330 |
| Proliferative | 299 (56) | 263 (57) | 36 (50) | |
| Not classifiable∗ | 5 (1) | 20 (1) | 0 | |
| Cytogenetics, n (%) | ||||
| Diploid | 334 (63) | 293 (64) | 41 (58) | .235 |
| Chr 5/5q abnormality | 12 (2) | 9 (2) | 3 (4) | .464 |
| Chr 7 abnormality | 27 (5) | 18 (4) | 9 (13) | .005 |
| Trisomy 8 | 40 (8) | 36 (8) | 4 (6) | .642 |
| del(13q) | 9 (2) | 7 (2) | 2 (3) | .794 |
| del(20q) | 19 (4) | 16 (3) | 3 (4) | .999 |
| Complex | 18 (3) | 13 (3) | 5 (7) | .154 |
| CPSS CG classification, n (%) | ||||
| Favorable | 328 (62) | 284 (62) | 44 (62) | .917 |
| Intermediate | 89 (17) | 77 (17) | 12 (17) | |
| Adverse | 79 (15) | 67 (15) | 12 (17) | |
| Not classifiable∗ | 36 (6) | 33 (6) | 3 (4) | |
| CPSS-Mol risk group, n (%) | ||||
| Low | 26 (5) | 24 (5) | 2 (3) | .792 |
| Intermediate-1 | 70 (13) | 59 (13) | 11 (15) | |
| Intermediate-2 | 150 (28) | 129 (28) | 21 (30) | |
| High | 113 (21) | 97 (21) | 16 (23) | |
| Not classifiable∗ | 173 (33) | 153 (33) | 21 (29) | |
| Characteristic . | All patients (N = 532) . | Patients with dnCMML (n = 461) . | Patients with tCMML (n = 71) . | P value . |
|---|---|---|---|---|
| Median age, y (range) | 70 (25-94) | 70 (25-94) | 73 (30-89) | .055 |
| Male sex, n (%) | 358 (67) | 309 (67) | 49 (69) | .844 |
| Median hemoglobin level, g/dL (range) | 10.8 (5.3-17.3) | 10.8 (5.3-17.3) | 10.9 (6.4-15.6) | .530 |
| Median WBC count, ×109 cells/L (range) | 12.6 (2.4-214.0) | 13.3 (2.6-214.0) | 10.7 (2.4-132.9) | .030 |
| Median absolute neutrophil count, ×109 cells/L (range) | 6.5 (0-108.0) | 6.8 (0-108.0) | 5.3 (0.5-50.6) | .100 |
| Median absolute monocyte count, ×109 cells/L (range) | 2.4 (1-74.7) | 2.4 (1-74.7) | 1.9 (1-73.1) | .698 |
| Median platelet count, ×109 cells/L (range) | 101 (7-1386) | 101 (7-1386) | 115 (16-638) | .629 |
| Median bone marrow blast percentage (range) | 6 (0-18) | 6 (0-18) | 5 (1-18) | .879 |
| WHO 2016 classification, n (%) | ||||
| CMML-0 | 206 (39) | 176 (38) | 30 (42) | .840 |
| CMML-1 | 205 (39) | 179 (39) | 26 (37) | |
| CMML-2 | 116 (22) | 101 (22) | 15 (21) | |
| Not classifiable∗ | 5 (1) | 5 (1) | 0 | |
| FAB CMML classification, n (%) | ||||
| Dysplastic | 228 (43) | 193 (42) | 35 (49) | .330 |
| Proliferative | 299 (56) | 263 (57) | 36 (50) | |
| Not classifiable∗ | 5 (1) | 20 (1) | 0 | |
| Cytogenetics, n (%) | ||||
| Diploid | 334 (63) | 293 (64) | 41 (58) | .235 |
| Chr 5/5q abnormality | 12 (2) | 9 (2) | 3 (4) | .464 |
| Chr 7 abnormality | 27 (5) | 18 (4) | 9 (13) | .005 |
| Trisomy 8 | 40 (8) | 36 (8) | 4 (6) | .642 |
| del(13q) | 9 (2) | 7 (2) | 2 (3) | .794 |
| del(20q) | 19 (4) | 16 (3) | 3 (4) | .999 |
| Complex | 18 (3) | 13 (3) | 5 (7) | .154 |
| CPSS CG classification, n (%) | ||||
| Favorable | 328 (62) | 284 (62) | 44 (62) | .917 |
| Intermediate | 89 (17) | 77 (17) | 12 (17) | |
| Adverse | 79 (15) | 67 (15) | 12 (17) | |
| Not classifiable∗ | 36 (6) | 33 (6) | 3 (4) | |
| CPSS-Mol risk group, n (%) | ||||
| Low | 26 (5) | 24 (5) | 2 (3) | .792 |
| Intermediate-1 | 70 (13) | 59 (13) | 11 (15) | |
| Intermediate-2 | 150 (28) | 129 (28) | 21 (30) | |
| High | 113 (21) | 97 (21) | 16 (23) | |
| Not classifiable∗ | 173 (33) | 153 (33) | 21 (29) | |
CG, cytogenetic; Chr, chromosome; FAB, French-American-British; WBC, white blood cell.
Patients not classifiable because of unavailable laboratory, cytogenetic, or genetic data.